Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy.
about
Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient.Antigen Cross-Presentation and T-Cell Cross-Priming In Cancer Immunology And Immunotherapy.Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy.Versican-Derived Matrikines Regulate Batf3-Dendritic Cell Differentiation and Promote T Cell Infiltration in Colorectal Cancer.Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses.Combined sublethal irradiation and agonist anti-CD40 enhance donor T cell accumulation and control of autochthonous murine pancreatic tumors.Dendritic Cell-Based Cancer Vaccines.Inhibitors of the PD-1 Pathway in Tumor Therapy.Overexpression of adhesion molecules and barrier molecules is associated with differential infiltration of immune cells in non-small cell lung cancer.Epithelial-mesenchymal transition (EMT) signature is inversely associated with T-cell infiltration in non-small cell lung cancer (NSCLC).Paracrine Wnt5a-β-Catenin Signaling Triggers a Metabolic Program that Drives Dendritic Cell Tolerization.Emerging biomarkers for cancer immunotherapy in melanoma.NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control.Genetic mechanisms of immune evasion in colorectal cancer.A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment.Understanding the tumor immune microenvironment (TIME) for effective therapy.Deptor is a novel target of Wnt/β-catenin/c-Myc and contributes to colorectal cancer cell growth.Tumor-Resident Dendritic Cells and Macrophages Modulate the Accumulation of TCR-Engineered T Cells in Melanoma.Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance.Molecular regulation of dendritic cell development and function in homeostasis, inflammation, and cancer.CD103+ cells at the forefront of anticancer immunity.Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment.Prognosis of ovarian cancer is associated with effector memory CD8+ T cell accumulation in ascites, CXCL9 levels and activation-triggered signal transduction in T cells.Approaches to Improve Chemically Defined Synthetic Peptide Vaccines.Ilixadencel - an Allogeneic Cell-Based Anticancer Immune Primer for Intratumoral Administration.Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma.Trial watch: Immunogenic cell death induction by anticancer chemotherapeuticsAccelerated, but not conventional, radiotherapy of murine B-cell lymphoma induces potent T cell-mediated remissionsThe Role of CXCR3 and Its Chemokine Ligands in Skin Disease and CancerExploring optimal sequencing of radiation and immunotherapy combinationsLinCCR2 hematopoietic stem and progenitor cells overcome resistance to PD-1 blockadeTranscription factor Etv6 regulates functional differentiation of cross-presenting classical dendritic cellsNotch Signaling Facilitates In Vitro Generation of Cross-Presenting Classical Dendritic CellsActivation of viral defense signaling in cancerAdhesive Interactions Delineate the Topography of the Immune SynapseTreatment with mRNA coding for the necroptosis mediator MLKL induces antitumor immunity directed against neo-epitopesRegulation of Ovarian Cancer Prognosis by Immune Cells in the Tumor Microenvironment
P2860
Q41571576-5FB05210-57BA-4F8C-8DCF-1F6D0D686D78Q41930681-CE34D960-AB56-4240-A38A-E78780456334Q47193084-7603D002-B5A9-4CE6-90D8-F1A8E0E6DDBFQ47571709-0455C91A-AD08-49A1-96CD-86BD389C7D41Q47614555-9CD702F0-3B76-4103-9848-A6C107C66A7BQ48248569-63496667-3831-41A3-B2AD-06E615F8AC49Q48293590-82BD45EC-EF7B-444A-ADFC-53D70AD4C1C8Q48293633-C8A798FA-9CFD-4EFF-953C-4AAFB2CC57D0Q49166013-816D8530-B9ED-4C30-9B7C-7AE9C551CC67Q49243761-BD1D1614-D689-495C-ACBC-676697B173B8Q49990713-A9F640B5-B726-49D2-8D35-D0A3AD1A0FE1Q50058145-4891E396-D94C-4581-8510-B4D92D3148C0Q50076191-11542B2E-62C7-4DA7-BD86-D5591158DCBCQ50420634-EB888BFE-4286-4C66-9744-125A73DA6A25Q50538951-7EA9A837-31E0-4276-9512-0444397702FBQ52311744-EDAFB0FF-E5F6-4FE0-80C6-38A8B18F907CQ52582285-6E276F4B-9800-402C-8970-73C252ACA856Q52720866-98A40AA1-BD64-467E-A4C7-53197BA334A3Q52723482-C41F08FA-8816-45DA-8884-5BA2F00D79A3Q52726024-56F4D226-28B2-4A6A-AB7E-DD27B1E547DDQ52780158-2874EB02-6273-463C-BA30-D1378D5F999EQ53697047-62259408-889C-41BC-B098-3500A4DC33E3Q54958210-309EB2D0-F2C9-4496-93DA-248993DC7878Q54961397-8C5B5B4C-BDA4-4B88-BAAD-702B65CFABB4Q55380684-D2487975-74C3-47DE-9F8C-F8135E445D48Q55457224-1303DA15-6D9D-4625-939A-2D95771F6C2AQ56594845-2397B22F-C342-48E5-9C58-2B1A4EB5C293Q57287562-F9AC26C3-7842-44C9-A6E5-8B85C9AF72D0Q57492052-AA2C2922-DD9E-4B8D-8462-66ED9C15CB26Q58119202-05739C3F-F2BB-4312-A616-28B3C4D8699BQ58547242-A96B7E42-58C8-4CB7-AFAB-271563FF4971Q58620992-2EF62A2B-B924-4045-9885-DE24897EC008Q58620994-35597F69-4914-44B5-B742-2D75A1C087EAQ58695217-D5F2F917-C2D0-4EA6-9862-7D11029517CAQ58698089-63C035D6-F90B-4906-8312-4D3E6510ADCAQ58708239-1923C696-7067-46AD-941D-A71E644455B6Q58773649-DB29766D-BE5A-4AE1-B4BD-3DF0DE0AC683
P2860
Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Tumor-Residing Batf3 Dendritic ...... g and Adoptive T Cell Therapy.
@en
type
label
Tumor-Residing Batf3 Dendritic ...... g and Adoptive T Cell Therapy.
@en
prefLabel
Tumor-Residing Batf3 Dendritic ...... g and Adoptive T Cell Therapy.
@en
P2093
P2860
P1433
P1476
Tumor-Residing Batf3 Dendritic ...... g and Adoptive T Cell Therapy.
@en
P2093
Brendan Horton
Stefani Spranger
Thomas F Gajewski
P2860
P304
711-723.e4
P356
10.1016/J.CCELL.2017.04.003
P577
2017-05-01T00:00:00Z